What Could Merck (MRK) Reveal At ESMO 2026 About Its Oncology Pipeline?

Merck (NYSE:MRK) plans to unveil first-time pivotal Phase 3 oncology data at ESMO 2026, including melanoma and endometrial cancer trials. The company will share late-breaking results from multiple oncology pipeline programs that extend beyond its currently marketed cancer therapies. Merck is pairing the scientific presentations with an Oncology Investor Event focused on its next wave of cancer drug candidates and plans. The first-time pivotal Phase 3 oncology results at ESMO 2026 deserve to...